Drug discovery startup GTN lands £2.1m Seed from Octopus Ventures

May 4, 2018 · uktech.news

Noornew2 898x505

London-based startup GTN has raised £2.1m in Seed funding in a round led by Octopus Ventures to transform drug discovery.

Pentech and existing investor Entrepreneur First also contributed to the round, which will be used to build on GTN’s drug discovery technology.

On average, bringing a new drug to the market costs $2.9bn and takes 15 years, with a high chance of failure; plus an expected 50% drop in R&D output every nine years.

GTN, a female-led company, has developed a technology called Generative Tensorial Networks. It combines and builds upon techniques from machine learning and quantum physics to simulate, filter and discover new molecules. The company says this will help bring efficiencies to the drug development cycle, discovering much-needed medicines for patients with cancer, autoimmune and infectious diseases.

Read Complete Article

RT @MayorofLondon: EU citizens living in London are Londoners and will always be part of our city. If that’s you, sign up for information a…

I welcome the scrapping of plans for the Enderby Wharf Cruise Terminal, which raised significant concerns around th… https://t.co/LSXPhEPe5s

#TechX365: If the UK tech industry is so good at getting a #tech business to $1 billion, what's stopping it from gr… https://t.co/QmXv7kVeO2

New iPhone sales may be showing some signs of weakening, but that might not be a bad thing for Apple https://t.co/6DNGBtLfag by @the_pc_doc

🍒 😀 🍒 @lyvlylife are hiring an Executive Assistant https://t.co/dDT8vzFs81